二水4-羟基苯磺酸钠

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二水4-羟基苯磺酸钠
• 中文别名: 二水对羟基苯磺酸钠；4-羟基苯磺酸钠二水合物
• 英文名称: Sodium;4-sulfophenolate;dihydrate
• 英文别名: sodium;4-sulfophenolate;dihydrate
• 化学式: C6H9NaO6S
• 分子量: 232.19
• InChiKey: SXONATFNYJWFNK-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -4.35
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.8
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  二水4-羟基苯磺酸钠 在 甲苯 、 水 作用下， 以 sodium hydroxide 为溶剂， 反应 17.0h， 以to give 4-hydroxybenzenesulfonic acid disodium salt的产率得到Disodium p-sulfophenoxide
  参考文献：
  名称：

  Organic compounds

  摘要：

  该式化合物提供药理剂，可结合过氧化物酶体增殖物激活受体（PPARs）。因此，本发明的化合物对于治疗哺乳动物中由PPAR受体活性介导的疾病是有用的。这些疾病包括失调脂质代谢、高脂血症、高胆固醇血症、动脉粥样硬化、高三酸甘油酯血症、心力衰竭、心肌梗死、血管疾病、心血管疾病、高血压、肥胖、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼科疾病、炎症性肠病（IBD）、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物中作为降糖剂特别有用，用于治疗和预防因糖耐量受损、高血糖和胰岛素抵抗而引起的疾病，如1型和2型糖尿病和X综合征。

  公开号：

  US07700637B2

文献信息

• Heterocyclic compounds and methods of use
  申请人：——

  公开号：US20040248936A1

  公开（公告）日：2004-12-09

  Compounds of the formula 1 provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPAR&agr; and PPAR&ggr; receptors.

  式1的化合物提供了具有强效 Peroxisome Proliferator-Activated Receptors（PPARs）激动剂作用的药理剂。因此，本发明的化合物对哺乳动物体内由 PPAR 受体活性介导的疾病的治疗具有用处。这些疾病包括：血脂异常、高脂血症、高胆固醇血症、动脉硬化、高三酰甘油血症、心力衰竭、心肌梗塞、血管疾病、心血管疾病、高血压、肥胖、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼科疾病、炎症性肠病、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物体内特别有用，作为降血糖剂，用于治疗和预防与糖耐量受损、高血糖和胰岛素抵抗有关的疾病，如1型和2型糖尿病以及X综合征。本发明的优选化合物是 PPAR&agr; 和 PPAR&ggr; 双重激动剂。
• Novel pentafluorosulfanyl compounds
  申请人：Bossenmaier Birgit

  公开号：US20050197370A1

  公开（公告）日：2005-09-08

  The present invention provides the compounds of formula I-A their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明提供公式I-A化合物及其药学上可接受的盐或酯、对映体、非对映异构体和外消旋体，上述化合物的制备方法，含有它们的制药组合物及其制造方法，以及上述化合物在控制或预防癌症等疾病中的用途。
• Arylsulfonyl hydroxamic acid derivatives
  申请人：Pfizer Inc

  公开号：US06599890B1

  公开（公告）日：2003-07-29

  A compound of the formula wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

  一种化合物，其化学式为上述定义的R1、R2、R3、R4、R5、R6、R7、R8、R9和Q，可用于治疗所选疾病，包括关节炎、癌症、组织溃疡、黄斑变性、再狭窄、牙周病、表皮松解症、巩膜炎和其他以基质金属蛋白酶活性为特征的疾病、艾滋病、败血症、脓毒症休克和其他涉及TNF产生的疾病。此外，本发明的化合物可与标准非甾体抗炎药（NSAID'S）和镇痛药一起联合治疗，并与细胞毒性药物（如阿霉素、多柔比星、顺铂、依托泊苷、紫杉醇、替-taxotere和其他生物碱，如长春碱）联合使用，用于癌症治疗。
• Pentafluorosulfanyl compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US07235574B2

  公开（公告）日：2007-06-26

  The present invention provides the compounds of formula I-A their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明提供了式I-A化合物及其药学上可接受的盐或酯、对映体形式、二对映异构体和外消旋体，上述化合物的制备方法，含有它们的制药组合物及其制备方法，以及上述化合物在控制或预防癌症等疾病中的应用。
• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Bach Thomas Andrew

  公开号：US20070135502A1

  公开（公告）日：2007-06-14

  Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPARα and PPARγ receptors.

  该公式化合物提供了对过氧化物酶体增殖物激活受体（PPARs）具有强效激动剂作用的药理制剂。因此，本发明的化合物对于治疗哺乳动物PPAR受体活性介导的疾病是有用的。这些疾病包括：血脂异常、高血脂、高胆固醇血症、动脉粥样硬化、高三酰甘油血症、心力衰竭、心肌梗塞、血管疾病、心血管疾病、高血压、肥胖、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸道疾病、眼科疾病、炎症性肠病、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物中作为降糖剂特别有用，用于治疗和预防出现受损的葡萄糖耐受性、高血糖和胰岛素抵抗的疾病，例如1型和2型糖尿病和X综合症。本发明的化合物中，对于同时激活PPARα和PPARγ受体的双重激动剂，更为优选。